Brought to you by 
Sarepta raises $505mm through upsized convertible note offering
Nov 2017
Executive Summary
Sarepta Therapeutics Inc. (rare neuromuscular diseases) netted $505mm through the private placement of $570mm aggregate principal amount (including full exercise of a $95mm overallotment) of seven-year 1.5% convertible senior notes to qualified institutional purchasers, including the company's CEO, who purchased $2mm worth of shares. (Sarepta upsized the deal from its original intent to offer $375mm in notes with a $75mm overallotment.)
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com